PL3725803T3 - Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania - Google Patents

Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania

Info

Publication number
PL3725803T3
PL3725803T3 PL20165165T PL20165165T PL3725803T3 PL 3725803 T3 PL3725803 T3 PL 3725803T3 PL 20165165 T PL20165165 T PL 20165165T PL 20165165 T PL20165165 T PL 20165165T PL 3725803 T3 PL3725803 T3 PL 3725803T3
Authority
PL
Poland
Prior art keywords
binding molecules
complement factor
human complement
bind human
bind
Prior art date
Application number
PL20165165T
Other languages
English (en)
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Louis Boon
Petrus Johannes Simons
Original Assignee
Broteio Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B.V. filed Critical Broteio Pharma B.V.
Publication of PL3725803T3 publication Critical patent/PL3725803T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL20165165T 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania PL3725803T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof
EP20165165.0A EP3725803B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2b and uses thereof
EP14729463.1A EP2999714B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Publications (1)

Publication Number Publication Date
PL3725803T3 true PL3725803T3 (pl) 2022-04-04

Family

ID=48485015

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20165165T PL3725803T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Country Status (15)

Country Link
US (2) US9944717B2 (pl)
EP (2) EP2999714B1 (pl)
JP (3) JP2016520313A (pl)
CN (1) CN105492461B (pl)
AU (1) AU2014269193C1 (pl)
CA (1) CA2913318C (pl)
DK (2) DK2999714T3 (pl)
ES (2) ES2904709T3 (pl)
HK (1) HK1223385A1 (pl)
HU (2) HUE057858T2 (pl)
LT (2) LT3725803T (pl)
MX (1) MX366046B (pl)
PL (2) PL3725803T3 (pl)
PT (2) PT3725803T (pl)
WO (1) WO2014189378A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492461B (zh) * 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用
JP7069138B2 (ja) * 2016-10-12 2022-05-17 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗C1s抗体およびその使用方法
CA3119655A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
CN114502583A (zh) * 2019-08-12 2022-05-13 杰特创新股份有限公司 补体c2结合蛋白及其用途
CA3237883A1 (en) * 2022-01-29 2023-08-03 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
CN105492461B (zh) * 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Also Published As

Publication number Publication date
CN105492461A (zh) 2016-04-13
WO2014189378A1 (en) 2014-11-27
HK1223385A1 (zh) 2017-07-28
PT3725803T (pt) 2021-12-24
PT2999714T (pt) 2020-04-30
AU2014269193A1 (en) 2015-12-17
DK2999714T3 (da) 2020-06-02
CN105492461B (zh) 2019-11-26
LT3725803T (lt) 2022-03-10
MX366046B (es) 2019-06-26
JP2023002684A (ja) 2023-01-10
ES2904709T3 (es) 2022-04-05
EP2999714B1 (en) 2020-04-01
US20160108134A1 (en) 2016-04-21
CA2913318C (en) 2024-03-26
MX2015016120A (es) 2016-10-28
LT2999714T (lt) 2020-07-10
HUE057858T2 (hu) 2022-06-28
EP2999714A1 (en) 2016-03-30
HUE049769T2 (hu) 2020-10-28
DK3725803T3 (da) 2022-03-07
US10717785B2 (en) 2020-07-21
EP3725803B1 (en) 2021-12-15
JP2016520313A (ja) 2016-07-14
CA2913318A1 (en) 2014-11-27
AU2014269193C1 (en) 2020-02-20
PL2999714T3 (pl) 2020-10-19
JP7163254B2 (ja) 2022-10-31
US9944717B2 (en) 2018-04-17
AU2014269193B2 (en) 2019-08-15
JP7414929B2 (ja) 2024-01-16
EP3725803A1 (en) 2020-10-21
ES2784616T3 (es) 2020-09-29
US20180319895A1 (en) 2018-11-08
JP2020007318A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
HK1223629A1 (zh) 結合分子
IL254223A (en) CD20 binding compounds and their uses
HK1217502A1 (zh) 結合蛋白及其應用
HK1222182A1 (zh) 三聚體抗原結合分子
HK1223385A1 (zh) 結合人類補體因子 的結合分子及其應用
ZA201506186B (en) Ligand binding molecules and uses thereof
HK1258317A1 (zh) 對asct2具有特異性的結合分子及其用途
GB201306588D0 (en) Peptides and Binding Partners Therefor
ZA201503962B (en) Fines binding process and binding composition thereof
HU4488U (en) Plaster-coated and edge-protected chipboard